Back to Search Start Over

Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database.

Authors :
Alcalde-Cabero, Enrique
Almazán-Isla, Javier
García López, Fernando J.
Ara-Callizo, José Ramón
Avellanal, Fuencisla
Casasnovas, Carlos
Cemillán, Carlos
Cuadrado, José Ignacio
Duarte, Jacinto
Fernández-Pérez, María Dolores
Fernández, Óscar
García Merino, Juan Antonio
Montero, Rosa García
Montero, Dolores
Pardo, Julio
Rodríguez-Rivera, Francisco Javier
Ruiz-Tovar, María
de Pedro-Cuesta, Jesús
Merino, Juan Antonio García
Spanish GBS Epidemiology Study Group
Source :
BMC Neurology; 5/21/2016, Vol. 16, p1-13, 13p, 4 Charts, 2 Graphs, 1 Map
Publication Year :
2016

Abstract

<bold>Background: </bold>Studies have shown a slight excess risk in Guillain-Barré syndrome (GBS) incidence associated with A(H1N1)pdm09 vaccination campaign and seasonal trivalent influenza vaccine immunisations in 2009-2010. We aimed to assess the incidence of GBS as a potential adverse effect of A(H1N1)pdm09 vaccination. <bold>Methods: </bold>A neurologist-led network, active at the neurology departments of ten general hospitals serving an adult population of 4.68 million, conducted GBS surveillance in Spain in 2009-2011. The network, established in 1996, carried out a retrospective and a prospective study to estimate monthly alarm thresholds in GBS incidence and tested them in 1998-1999 in a pilot study. Such incidence thresholds additionally to observation of GBS cases with immunisation antecedent in the 42 days prior to clinical onset were taken as alarm signals for 2009-2011, since November 2009 onwards. For purpose of surveillance, in 2009 we updated both the available centres and the populations served by the network. We also did a retrospective countrywide review of hospital-discharged patients having ICD-9-CM code 357.0 (acute infective polyneuritis) as their principal diagnosis from January 2009 to December 2011. <bold>Results: </bold>Among 141 confirmed of 148 notified cases of GBS or Miller-Fisher syndrome, Brighton 1-2 criteria in 96 %, not a single patient was identified with clinical onset during the 42-day time interval following A(H1N1)pdm09 vaccination. In contrast, seven cases were seen during a similar period after seasonal campaigns. Monthly incidence figures did not, however, exceed the upper 95 % CI limit of expected incidence. A retrospective countrywide review of the registry of hospital-discharged patients having ICD-9-CM code 357.0 (acute infective polyneuritis) as their principal diagnosis did not suggest higher admission rates in critical months across the period December 2009-February 2010. <bold>Conclusions: </bold>Despite limited power and underlying reporting bias in 2010-2011, an increase in GBS incidence over background GBS, associated with A(H1N1)pdm09 monovalent or trivalent influenza immunisations, appears unlikely. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14712377
Volume :
16
Database :
Complementary Index
Journal :
BMC Neurology
Publication Type :
Academic Journal
Accession number :
115584740
Full Text :
https://doi.org/10.1186/s12883-016-0598-z